Apogee Therapeutics, Inc. - 8-K Filing
Apogee Therapeutics entered into an antibody discovery agreement and a related license agreement with Paragon Therapeutics on June 17, 2026. Under the agreements, Apogee will pay up to $23.25 million in milestone payments for development achievements, including $5.25 million upon first dosing of a human patient in a Phase I trial, and low-single-digit royalties on net sales under the license agreement. (Items: 1.01 Entry into a Material Definitive Agreement, 9.01 Financial Statements and Exhibits)
Tickers: $APGE